Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:55:22 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

T:MDNA - MEDICENNA THERAPEUTICS CORP. J - https://www.medicenna.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MDNA - T  5.00.81·0.870.50.84-0.04-4.538.330640.88  0.89  0.822.625  0.7815:59:47Jun 2615 min RT 2¢
TSX - T5.00.81·0.870.50.84-0.04-4.517.914220.88  0.88  0.822.625  0.7815:59:4715 min
NEO ATS - U 0.84-0.04-4.56.5560.86  0.86  0.8314:57:4315 min
Alpha - A 0.85-0.03-3.41.7140.86  0.86  0.8415:27:1615 min
Omega - O 0.84-0.04-4.52.5240.86  0.89  0.8413:30:3015 min
Chi-X - X 0.87-0.01-1.10.5010.87  0.87  0.8712:05:0715 min
CX2 - H 0.84-0.04-4.55.5540.86  0.86  0.8413:31:3715 min
CXD - D 0.881.109    Jul 1515 min
TriAct - M 0.880.9012    Sep 11/2015 min
Lynx - Y 0.84-0.04-4.51.5110.84  0.84  0.8412:48:2115 min
CS2 - S 0.880.301    Jul 3115 min

Recent Trades - Last 10 of 64
Time ETExPriceChangeVolumeBuyerSellerMarkers
15:59:47T0.84-0.0450080 National Bank79 CIBCK
15:59:47D0.84-0.041027 TD Sec7 TD SecE
15:59:47T0.84-0.06880 National Bank80 National Bank
15:59:47T0.84-0.0640080 National Bank5 Citadel
15:59:47T0.84-0.063009 BMO Nesbitt80 National Bank
15:59:47T0.84-0.0616880 National Bank5 Citadel
15:59:47T0.84-0.06275124 Questrade80 National Bank
15:59:43T0.82-0.061,00019 Desjardins80 National BankK
15:54:01M0.82-0.06580 National Bank80 National BankE
15:53:18M0.82-0.0610079 CIBC79 CIBCE

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2025-06-26 07:00C:MDNA0.91News ReleaseMedicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights
2025-06-25 21:11C:MDNA0.91SEDAR Annual Information FormSEDAR Annual Information Form
2025-06-25 21:05C:MDNA0.91SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2025-06-25 21:05C:MDNA0.91SEDAR MD & ASEDAR MD & A
2025-05-02 14:42C:MDNA1.22SEDAR Preliminary Short Form ProspectusSEDAR Preliminary Short Form Prospectus
2025-05-02 10:00C:MDNASEDAR Final Short Form ProspectusSEDAR Final Short Form Prospectus
2025-04-30 18:09C:MDNA1.16News ReleaseMedicenna presents preclinical MDNA113 data at meeting
2025-04-28 19:36C:MDNA1.10News ReleaseMedicenna's MDNA11 showing acceptable safety profile
2025-04-22 07:00C:MDNA1.06News ReleaseMedicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
2025-04-01 07:00C:MDNA0.98News ReleaseMedicenna to Present at Jones Healthcare and Technology Innovation Conference
2025-03-26 15:24C:MDNA0.99News ReleaseMedicenna to present MDNA11 update at AACR
2025-02-25 15:46C:MDNA1.13News ReleaseMedicenna talks MDNA11 Ability-1 study data
2025-02-13 10:28C:MDNA1.27News ReleaseMedicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
2025-02-12 21:03C:MDNA1.27SEDAR Interim MD & ASEDAR Interim MD & A
2025-02-05 07:00C:MDNA1.26News ReleaseMedicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
2024-12-13 08:30C:MDNA1.81News ReleaseMedicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
2024-12-05 07:35C:MDNA1.66News ReleaseMedicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA(TM) (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study
2024-11-27 07:00C:MDNA1.77News ReleaseUpdated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference
2024-11-25 07:30C:MDNA1.57News ReleaseMedicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)
2024-11-15 07:30C:MDNA1.70News ReleaseMedicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update